Donald R. VanDevanter

Also affiliated with Case Western Reserve University

MedicineSocial Sciences

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 21 papers. Top paper: “Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials”.

Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials

Journal of Cystic Fibrosis(2020)10.1016/j.jcf.2020.07.008

N/A

0.930DataRank · unranked

18 citations

N. Hamblett, Noah Simon, Joseph McIntosh, Michael W. Konstan, Donald R. VanDevanter

Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations

Annals of the American Thoracic Society(2023)10.1513/annalsats.202306-576oc

N/A

0.703DataRank · unranked

20 citations

Lindsay J. Caverly, Linda M. Kalikin, Lisa A. Carmody, Scott McClellan, William LeBar +8 more

Health care costs in a randomized trial of antimicrobial duration among cystic fibrosis patients with pulmonary exacerbations

Journal of Cystic Fibrosis(2022)10.1016/j.jcf.2022.03.001

N/A

0.357DataRank · unranked

6 citations

Ryan N. Hansen, Donald L. Patrick, Ashley Tabah, Sonya L. Heltshe, Patrick A. Flume +6 more

Willingness of people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor (ETI) to participate in randomized modulator and inhaled antimicrobial clinical trials

Journal of Cystic Fibrosis(2023)10.1016/j.jcf.2023.04.007

N/A

0.347DataRank · unranked

5 citations

Edith T. Zemanick, Michael W. Konstan, Clement L. Ren, Katherine Odem‐Davis, I. Emerman +3 more

Finding the relevance of antimicrobial stewardship for cystic fibrosis

Journal of Cystic Fibrosis(2020)10.1016/j.jcf.2020.02.012

N/A

0DataRank · unranked

29 citations

Barbara C. Kahl, Holly Maples, Susanna A. McColley, Jason A. Roberts, Kevin Winthrop +10 more

Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study

Journal of Cystic Fibrosis(2021)10.1016/j.jcf.2021.01.011

N/A

0DataRank · unranked

24 citations

Michael W. Konstan, Donald R. VanDevanter, Steven M. Rowe, JP Clancy, Katherine Odem‐Davis +3 more

Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation

Journal of Cystic Fibrosis(2021)10.1016/j.jcf.2021.11.009

N/A

0DataRank · unranked

19 citations

Umer Khan, Sonya L. Heltshe, M. Skalland, Natalie E. West, Donald R. VanDevanter +3 more

Antipseudomonal treatment decisions during CF exacerbation management

Journal of Cystic Fibrosis(2022)10.1016/j.jcf.2022.04.006

N/A

0DataRank · unranked

12 citations

Natalie E. West, Don B. Sanders, M. Skalland, Christopher H. Goss, Patrick A. Flume +2 more

Changes in airway bacterial communities occur soon after initiation of antibiotic treatment of pulmonary exacerbations in cystic fibrosis

Journal of Cystic Fibrosis(2022)10.1016/j.jcf.2022.05.011

N/A

0DataRank · unranked

12 citations

Linda M. Kalikin, Donald R. VanDevanter, Gen Li, Kristopher Opron, Richard H. Simon +3 more

Characterizing CFTR modulated sweat chloride response across the cf population: Initial results from the CHEC-SC study

Journal of Cystic Fibrosis(2022)10.1016/j.jcf.2022.07.008

N/A

0DataRank · unranked

8 citations

Edith T. Zemanick, Katherine Odem‐Davis, Donald R. VanDevanter, Mark N. Warden, Steven M. Rowe +4 more

Accelerated Approval or Risk Reduction? How Response Biomarkers Advance Therapeutics through Clinical Trials in Cystic Fibrosis

Trends in Molecular Medicine(2020)10.1016/j.molmed.2020.08.002

N/A

0DataRank · unranked

9 citations

Donald R. VanDevanter, Nicole Mayer-Hamblett

Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis

Journal of Cystic Fibrosis(2020)10.1016/j.jcf.2020.05.008

N/A

0DataRank · unranked

13 citations

Sonya L. Heltshe, Jay B. Hilliard, Michael W. Konstan, Donald R. VanDevanter

Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis

Annals of the American Thoracic Society(2023)10.1513/annalsats.202308-673oc

N/A

0DataRank · unranked

18 citations

Sonya L. Heltshe, Katherine Odem‐Davis, Natalie E. West, Don B. Sanders, B. Fogarty +4 more

Longitudinal bacterial prevalence in cystic fibrosis airways: Fact and artifact

Journal of Cystic Fibrosis(2023)10.1016/j.jcf.2023.09.011

N/A

0DataRank · unranked

15 citations

John J. LiPuma, Michael W. Konstan, Donald R. VanDevanter

Re-examining baseline lung function recovery following IV-treated pulmonary exacerbations

Journal of Cystic Fibrosis(2023)10.1016/j.jcf.2023.02.006

N/A

0DataRank · unranked

11 citations

Renee Russell, Donald R. VanDevanter, Don B. Sanders, Sonya L. Heltshe

Impact of lumacaftor/ivacaftor and tezacaftor/ivacaftor on treatment response in pulmonary exacerbations of F508del/F508del cystic fibrosis

Journal of Cystic Fibrosis(2023)10.1016/j.jcf.2023.06.012

N/A

0DataRank · unranked

10 citations

Sonya L. Heltshe, Katherine Odem‐Davis, Natalie E. West, Don B. Sanders, B. Fogarty +4 more

Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis

Journal of Cystic Fibrosis(2024)10.1016/j.jcf.2024.02.001

N/A

0DataRank · unranked

26 citations

I. Emerman, Morgan McCreary, N. Mayer-Hamblett, Mark N. Warden, Katherine Odem‐Davis +5 more

Daily variability of Pseudomonas aeruginosa density in cystic fibrosis sputum

Journal of Cystic Fibrosis(2024)10.1016/j.jcf.2024.11.013

N/A

0DataRank · unranked

2 citations

Lindsay J. Caverly, Linda M. Kalikin, Christina S. Thornton, Richard H. Simon, Donald R. VanDevanter +2 more

Correlates of FEV₁ deficit in pulmonary exacerbations of cystic fibrosis and associated clinical outcomes

Journal of Cystic Fibrosis(2025)10.1016/j.jcf.2025.12.007

N/A

0DataRank · unranked

0 citations

Sonya L. Heltshe, Don B. Sanders, Natalie E. West, B. Fogarty, Donald R. VanDevanter +3 more

Building global development strategies for cf therapeutics during a transitional cftr modulator era

Journal of Cystic Fibrosis(2020)10.1016/j.jcf.2020.05.011

N/A

0DataRank · unranked

31 citations

Silke van Koningsbruggen‐Rietschel, David P. Nichols, Donald R. VanDevanter, Jane C. Davies, T. Lee +20 more

Evaluating the association of antibiotic spectrum and treatment responses of cystic fibrosis pulmonary exacerbations

Journal of Cystic Fibrosis(2025)10.1016/j.jcf.2025.12.003

N/A

0DataRank · unranked

0 citations

Jonathan D. Cogen, Donald R. VanDevanter, John J. LiPuma, Natalie E. West, Don B. Sanders +6 more